
## Steven McKinney

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3166859/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461. Scientific Reports, 2021, 11, 9812.	3.3	9
2	Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects. Nature Cancer, 2020, 1, 518-532.	13.2	11
3	Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature, 2019, 567, 399-404.	27.8	239
4	Integrated structural variation and point mutation signatures in cancer genomes using correlated topic models. PLoS Computational Biology, 2019, 15, e1006799.	3.2	44
5	CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. Nature Communications, 2017, 8, 14432.	12.8	379
6	CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor. Nature Communications, 2017, 8, 7.	12.8	108
7	The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. Nature Communications, 2016, 7, 11479.	12.8	1,221
8	A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation. Breast Cancer Research, 2015, 17, 4.	5.0	24
9	A tumor DNA complex aberration index is an independent predictor of survival in breast and ovarian cancer. Molecular Oncology, 2015, 9, 115-127.	4.6	38
10	Does age influence the intrinsic biology of breast cancer?. Journal of Clinical Oncology, 2015, 33, 11044-11044.	1.6	0
11	Up-regulation of the interferon-related genes in BRCA2 knockout epithelial cells. Journal of Pathology, 2014, 234, 386-397.	4.5	25
12	The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature, 2012, 486, 346-352.	27.8	4,708
13	Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype. Clinical Cancer Research, 2008, 14, 1368-1376.	7.0	1,040